| ||
| Personalised First-Line Therapy Stalls Lung Cancer For Nearly Twice As Long As ... Medical News Today (press release) Roche today announced results from the first Phase III study with erlotinib (Tarceva®) in Western patients with a genetically mutated type of advanced non-small cell lung cancer (NSCLC). Results showed that first-line treatment with erlotinib nearly ... See all stories on this topic » | ||
| ||
| Oxigene rallies 30% ahead of study presentations MarketWatch The biotech group will present data from a study of the compound in the treatment of lung cancer on June 4. Data from a study of the drug for the treatment of head and neck cancer will be presented on June 6. "The US has a big budget problem over the ... See all stories on this topic » | ||
| ||
| FDA Drug Safety Communication: No Increase in Risk of Cancer With Certain ... PharmaLive.com (press release) Know that FDA's meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients ... See all stories on this topic » |
| ||
| Scientists Develop A "disperse Bombs" Toward Cancer mark | THE ... By admin While chemotherapies be an effectual treatment against cancer, is the shotgun approach also harm healthy cells make incapacitating surface belongings like ... ... According toward the Dr. Peer nano-medicine that can handle a variety of cancers such as lung, bloods, colons, breast, ovarian dissimilar category, pancreatic, and even different brain tumors. candy coating ... THE TECHNOLOGY REVIEW - http://thetechnologyreview.net/ |
| ||
| Latest Treatment In Lung Cancer News www.nucleusinc.com This 3D healthcare animation starts with an overview of the treatment choices for lung cancer. Diverse surgical choices these as a wedge ... lungcancerdefects.com/?p=203 |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment